CD33-directed Immunoconjugate [EPC]

3665 reported adverse events

Drugs of this class: GEMTUZUMAB OZOGAMICIN

These side effects are most commonly reported by patients taking drugs of the CD33-directed Immunoconjugate [EPC] class:

# Side effect Count
0 FEBRILE NEUTROPENIA 698
1 PYREXIA 326
2 SEPSIS 302
3 VENOOCCLUSIVE LIVER DISEASE 260
4 THROMBOCYTOPENIA 240
5 PLATELET COUNT DECREASED 236
6 PNEUMONIA 197
7 NEUTROPENIA 194
8 WHITE BLOOD CELL COUNT DECREASED 185
9 ASPARTATE AMINOTRANSFERASE INCREASED 184
See all common reactions for CD33-directed Immunoconjugate [EPC]

Drugs of the CD33-directed Immunoconjugate [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 GRANULICATELLA INFECTION 11 0.2619
1 GENOTOXICITY 5 0.1316
2 REFRACTORINESS TO PLATELET TRANSFUSION 6 0.0550
3 FIBRIN DEGRADATION PRODUCTS INCREASED 16 0.0541
4 VENOOCCLUSIVE LIVER DISEASE 260 0.0526
5 BACTERIA BLOOD IDENTIFIED 6 0.0458
6 VENOOCCLUSIVE DISEASE 109 0.0435
7 CONGENITAL APLASIA 10 0.0322
8 LOWER RESPIRATORY TRACT INFECTION FUNGAL 12 0.0308
9 ACUTE MONOCYTIC LEUKAEMIA 5 0.0275
See all enriched reactions for CD33-directed Immunoconjugate [EPC]